Choice ✔ investment

Choose stocks

Create and
share portfolios

Study reporting
public companies

ABUS - Company Financial Ratios

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1

United States    http://www.arbutusbio.com
Healthcare Biotechnology NASDAQ | Nasdaq Global Select

1.828 4.44

period
2021 3.82 303.64 - 8.89 0.00 0.00 1.93 0.000 0.00 0.49 20.92 - 54.96 - 78.26
2019 2.79 159.00 - 1.04 0.01 2.19 7.000 0.20 0.45 26.50 - 145.66 - 211.32
2018 3.71 205.00 - 3.60 0.03 1.02 - 4.920 - 0.18 0.14 34.51 - 25.04 - 28.50
2017 5.15 282.00 - 3.34 0.03 1.54 0.000 0.00 0.30 26.34 - 35.59 - 46.26
2016 2.55 135.00 - 0.35 0.00 0.67 0.000 0.00 0.36 90.77 - 139.23 - 189.24
2015 3.14 143.00 - 2.34 0.02 0.26 0.000 0.00 0.30 5.74 - 8.58 - 11.16